Clinical Evaluation of the Magnesium Absorption Kinetics in Human Plasma Upon Oral Intake of Magnesium-based Products

Launched by BIONOS BIOTECH S.L. · Jan 24, 2024

Keywords

ClinConnect Summary

Magnesium is essential to the basic nucleic acid chemistry of all cells in all known living organisms. It is essential for DNA, RNA, and ATP synthesis, as well as for many other biological functions. Oral supplementation may improve the dietary intake of magnesium, which has been identified as a shortfall nutrient. In this study, the investigators will investigate the bioavailability of four magnesium-based products as food supplements by quantifying the magnesium levels in the plasma of volunteers after oral intake.

The study will be a double-blind trial to compare the bioavailability of ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy volunteers between 20 and 55 years of all races/ethnicities.
• • Body mass index of 18-35 kg/m2.
• • Last participation in a clinical study of this type must be at least 15 days before the start of this study.
• • Fasting conditions during 8 hours before the experiment (with the exception of low mineralization water).
• • No consumption of food supplements or specific food containing high levels of magnesium (see attachment) during the week before the start of the treatment.
• Exclusion Criteria:
• • People with gastrointestinal diseases (diabetes, gastritis, Crohn's disease, celiac disease, ulcers, intolerances, etc.).
• • People with cardiorespiratory diseases (chronic bronchitis, chronic obstructive pulmonary disease, pulmonary emphysema, asthma and bronchiectasis, thrombi, heart disease, heart disorders, arrhythmias, insufficiencies, etc.).
• • Pregnant or lactating women or who plan to become pregnant during the study.
• • People under medical treatment in the weeks prior to the study that could interfere with the evaluations of the present study (according to the investigator's criteria).
• • People who are within a dietary period outside their usual habit.
• • People who demonstrate manifest incapacity to understand or follow the protocol or the informed consent.
• • Allergy or reactivity to any of the components of the product, or to a product with a category similar to the tested one.
• • Surgically operated for a heart condition.
• • People with forecast of changing routine or relevant way of life, during the period of the study.